Showing 2121-2130 of 5643 results for "".
- Call for Nominations: Prevent Blindness Seeks to Honor Leaders in Vision Healthhttps://modernod.com/news/call-for-nominations-prevent-blindness-seeks-to-honor-leaders-in-vision-health/2482661/Prevent Blindness, one of the nation’s largest eye health and safety nonprofit organizations, issued their call for nominations for the “
- Lumenis Launches OptiLIFT, Device to Address Lower Lid Laxity and Impaired Blinkinghttps://modernod.com/news/lumenis-launces-optilift-device-to-address-lower-lid-laxity-and-impaired-blinking/2482652/Lumenis announced the launch of OptiLIFT, a new device that uses Dynamic Muscle Stimulation technology (DMSt) to tone facial muscles to improve lower lid laxity and impaired blinking. OptiLIFT marks one of the first treatment options that eliminates the need for surgery. “Op
- Pykus Therapeutics to Present Initial Clinical Data on Novel Retinal Sealanthttps://modernod.com/news/pykus-therapeutics-to-present-initial-clinical-data-on-novel-retinal-sealant/2482651/Pykus Therapeutics announced that it will present initial clinical data on its investigational retinal sealant, PYK-2101, to replace gas and oil during retinal detachment repair. The data will be presented at the Vail Vitrectomy 2025 Meeting on February 10, 2025. The presentat
- Surgilūm's RoboMarker G2 Receives 5 International Medical Device Design Awardshttps://modernod.com/news/surgilums-robomarker-g2-receives-5-international-medical-device-design-awards/2482638/Surgilūm's RoboMarker G2 was awarded international medical device design awards by 3 associations. The awards include: New York Product Design Award: an international competition celebrating excellence in product desi
- Outlook Therapeutics Presents Results from NORSE EIGHT Trial Evaluating ONS-5010 for the Treatment of Wet AMDhttps://modernod.com/news/outlook-therapeutics-presents-efficacy-and-safety-results-from-norse-eight-trial-evaluating-ons-5010-for-the-treatment-of-wet-amd/2482632/Outlook Therapeutics announced the presentation of data from NORSE EIGHT at the Hawaiian Eye and Retina 2025 Meeting. Baruch D. Kuppermann, MD, PhD, of Gavin Herbert Eye Institute, University of California, Irvine, CA presented the abstract titled, “ONS-5010 (bevacizumab-vikg
- MERIT Acquires OSOD to Expand Ophthalmic Drug Development Serviceshttps://modernod.com/news/merit-acquires-osod-to-expand-ophthalmic-drug-development-services/2482629/MERIT announced its has acquired OSOD, which assists with ophthalmic preclinical drug development. The acquisition enhances MERIT’s capabilities, enabling a transition from preclinical to clinical phases of drug development. Accordin
- Pantheon Vision Advances Corneal Implant Developmenthttps://modernod.com/news/pantheon-vision-advances-corneal-implant-development/2482627/Pantheon Vision announced the completion of its third meeting with the FDA review team as the company continues its development of bioengineered corneal implants, designed to address the global challenge of corneal blindness. Over the past year, Pan
- Nacuity Pharmaceuticals Granted FDA Fast Track Designation for NPI-001 Tablets for RPhttps://modernod.com/news/nacuity-pharmaceuticals-granted-fda-fast-track-designation-for-npi-001-tablets-for-retinitis-pigmentosa/2482625/Nacuity Pharmaceuticals announced that the FDA has granted Fast Track Designation to NPI-001 (N-acetylcysteine amide) tablets, Nacuity’s proprietary investigational therapy for the treatment of patients with retinitis pigmentosa (RP). A drug may receive Fast Track designation
- Tangible Science Announces CEO Transitionhttps://modernod.com/news/tangible-science-announces-ceo-transition/2482613/Tangible Science, a provider of specialty contact lens technology, announced that Karen Havenstrite, PhD, MBA, co-founder and former Chief Technology Officer, has been appointed Chief Executive Officer. Dr. Havenstrite suceeds Victor McCray, MD, who will transition to the
- Bausch + Lomb Makes Two Deals to Bolster Therapeutic Pipeline in GA and Glaucomahttps://modernod.com/news/bausch-lomb-makes-two-deals-to-bolster-therapeutic-pipeline-in-ga-and-glaucoma/2482612/Bausch + Lomb announced two separate deals to acquire early- and mid-stage therapeutic assets. First, B+L, through an affiliate, acquired Whitecap Biosciences LLC, which is developing two therapies for potential use in glaucoma and geographic atrophy (GA). Financial terms